NCT00955487View on ClinicalTrials.gov

Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2014

Study Completion Date

December 31, 2014

Conditions
Bronchopulmonary Dysplasia
Interventions
DRUG

Inhaled Nitric Oxide (iNO)

iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).

DRUG

Nitrogen (placebo)

Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).

Trial Locations (6)

35242

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt Children's Hospital, Nashville

43205

Nationwide Children's Hospital, Columbus

60614

Anne and Robert H. Lurie Children's Hospital of Chicago and Northwestern Memorial Hospital, Chicago

80045

Children's Hospital and University Colorado Hospital, Aurora

92123

University of California San Diego, San Diego

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Colorado, Denver

OTHER

NCT00955487 - Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns | Biotech Hunter | Biotech Hunter